The pharmaceuticals group, Roche, and the Icelandic biotechnology company, Decode Genetics, say they are to begin a drug discovery programme to find new treatments and diagnostic tests for schizophrenia.This content was published on February 14, 2001 - 09:53
The two companies are also to collaborate to create new drugs for the treatment of a disease which causes the narrowing of the arteries.
Decode has identified genes linked to both illnesses. Roche pays Decode for its gene discoveries and has the rights to develop the company's findings into diagnostic products and medicines.
Decode has bought exclusive access to Iceland's health records and is gathering genetic information from the country's population.
swissinfo with agencies
This article was automatically imported from our old content management system. If you see any display errors, please let us know: email@example.com